Interim analysis of a phase 3 trial in 287 patients with pretreated HER2-positive metastatic breast cancer: trastuzumab rezetecan gave median PFS 30·6 vs 8·3 months with pyrotinib plus capecitabine (HR 0·22), with more grade ≥3 neutropenia (54% vs 9%).
RCTn = 287
Yao et al. Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial